← Back to patent-cliff list
Selgantolimod
Tier C — Watch / tradeSelgantolimod
Gilead Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TLR8
Indications (approved)：HIV infection, Hepatitis B, Chronic hepatitis B
Regional status
US
Phase II
2018-04-06
EU
Phase II
2021-08-14
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Selgantolimod?
Approved indications include: HIV infection, Hepatitis B, Chronic hepatitis B.
When does the Selgantolimod patent expire?
No public expiry year is available for Selgantolimod yet; this page updates once verified.
How do I get a quote for Selgantolimod intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08